Information Technology Services
Compare Stocks
2 / 10Stock Comparison
HIVE vs CLSK
Revenue, margins, valuation, and 5-year total return — side by side.
Software - Application
HIVE vs CLSK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Information Technology Services | Software - Application |
| Market Cap | $715M | $3.58B |
| Revenue (TTM) | $115M | $785M |
| Net Income (TTM) | $21M | $-261M |
| Gross Margin | 21.8% | 41.4% |
| Operating Margin | 1.4% | -26.4% |
| Forward P/E | — | 12.5x |
| Total Debt | $55M | $824M |
| Cash & Equiv. | $23M | $43M |
HIVE vs CLSK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| HIVE Digital Techno… (HIVE) | 100 | 212.6 | +112.6% |
| CleanSpark, Inc. (CLSK) | 100 | 695.5 | +595.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HIVE vs CLSK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HIVE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 3.16
- 27.7% 10Y total return vs CLSK's -84.3%
- Lower volatility, beta 3.16, Low D/E 12.3%, current ratio 3.72x
CLSK is the clearest fit if your priority is growth exposure.
- Rev growth 102.2%, EPS growth 262.3%, 3Y rev CAGR 79.9%
- 102.2% revenue growth vs HIVE's 0.7%
- 0.2% yield; 2-year raise streak; the other pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 102.2% revenue growth vs HIVE's 0.7% | |
| Quality / Margins | -2.6% margin vs CLSK's -33.2% | |
| Stability / Safety | Beta 3.16 vs CLSK's 3.39, lower leverage | |
| Dividends | 0.2% yield; 2-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +74.1% vs HIVE's +65.9% | |
| Efficiency (ROA) | 3.0% ROA vs CLSK's -8.5%, ROIC 0.3% vs 10.3% |
HIVE vs CLSK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
HIVE vs CLSK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
HIVE leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CLSK is the larger business by revenue, generating $785M annually — 6.8x HIVE's $115M. HIVE is the more profitable business, keeping -2.6% of every revenue dollar as net income compared to CLSK's -33.2%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $115M | $785M |
| EBITDAEarnings before interest/tax | $119M | $181M |
| Net IncomeAfter-tax profit | $21M | -$261M |
| Free Cash FlowCash after capex | -$196M | -$1.0B |
| Gross MarginGross profit ÷ Revenue | +21.8% | +41.4% |
| Operating MarginEBIT ÷ Revenue | +1.4% | -26.4% |
| Net MarginNet income ÷ Revenue | -2.6% | -33.2% |
| FCF MarginFCF ÷ Revenue | -136.8% | -133.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +11.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -8.4% | -2.6% |
Valuation Metrics
Evenly matched — HIVE and CLSK each lead in 2 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, CLSK's 6.5x EV/EBITDA is more attractive than HIVE's 11.7x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $715M | $3.6B |
| Enterprise ValueMkt cap + debt − cash | $747M | $4.4B |
| Trailing P/EPrice ÷ TTM EPS | -122.65x | 12.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 11.73x | 6.53x |
| Price / SalesMarket cap ÷ Revenue | 6.20x | 4.67x |
| Price / BookPrice ÷ Book value/share | 0.82x | 2.04x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
HIVE leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HIVE delivers a 3.3% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-14 for CLSK. HIVE carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to CLSK's 0.38x. On the Piotroski fundamental quality scale (0–9), CLSK scores 5/9 vs HIVE's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +3.3% | -13.7% |
| ROA (TTM)Return on assets | +3.0% | -8.5% |
| ROICReturn on invested capital | +0.3% | +10.3% |
| ROCEReturn on capital employed | +0.4% | +13.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.12x | 0.38x |
| Net DebtTotal debt minus cash | $32M | $781M |
| Cash & Equiv.Liquid assets | $23M | $43M |
| Total DebtShort + long-term debt | $55M | $824M |
| Interest CoverageEBIT ÷ Interest expense | -9.90x | -18.49x |
Total Returns (Dividends Reinvested)
CLSK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CLSK five years ago would be worth $7,306 today (with dividends reinvested), compared to $1,766 for HIVE. Over the past 12 months, CLSK leads with a +74.1% total return vs HIVE's +65.9%. The 3-year compound annual growth rate (CAGR) favors CLSK at 48.8% vs HIVE's -2.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +5.1% | +21.0% |
| 1-Year ReturnPast 12 months | +65.9% | +74.1% |
| 3-Year ReturnCumulative with dividends | -6.5% | +229.7% |
| 5-Year ReturnCumulative with dividends | -82.3% | -26.9% |
| 10-Year ReturnCumulative with dividends | +2770.0% | -84.3% |
| CAGR (3Y)Annualised 3-year return | -2.2% | +48.8% |
Risk & Volatility
Evenly matched — HIVE and CLSK each lead in 1 of 2 comparable metrics.
Risk & Volatility
HIVE is the less volatile stock with a 3.16 beta — it tends to amplify market swings less than CLSK's 3.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLSK currently trades 59.2% from its 52-week high vs HIVE's 36.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.16x | 3.39x |
| 52-Week HighHighest price in past year | $7.84 | $23.61 |
| 52-Week LowLowest price in past year | $1.60 | $7.91 |
| % of 52W HighCurrent price vs 52-week peak | +36.6% | +59.2% |
| RSI (14)Momentum oscillator 0–100 | 68.7 | 71.5 |
| Avg Volume (50D)Average daily shares traded | 13.3M | 19.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HIVE as "Buy" and CLSK as "Buy". Consensus price targets imply 62.7% upside for HIVE (target: $5) vs 44.6% for CLSK (target: $20). CLSK is the only dividend payer here at 0.24% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $4.67 | $20.21 |
| # AnalystsCovering analysts | 9 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | +0.2% |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | $0.03 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.1% |
HIVE leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CLSK leads in 1 (Total Returns). 2 tied.
HIVE vs CLSK: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is HIVE or CLSK a better buy right now?
For growth investors, CleanSpark, Inc.
(CLSK) is the stronger pick with 102. 2% revenue growth year-over-year, versus 0. 7% for HIVE Digital Technologies Ltd. (HIVE). CleanSpark, Inc. (CLSK) offers the better valuation at 12. 5x trailing P/E, making it the more compelling value choice. Analysts rate HIVE Digital Technologies Ltd. (HIVE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HIVE or CLSK?
Over the past 5 years, CleanSpark, Inc.
(CLSK) delivered a total return of -26. 9%, compared to -82. 3% for HIVE Digital Technologies Ltd. (HIVE). Over 10 years, the gap is even starker: HIVE returned +27. 7% versus CLSK's -84. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HIVE or CLSK?
By beta (market sensitivity over 5 years), HIVE Digital Technologies Ltd.
(HIVE) is the lower-risk stock at 3. 16β versus CleanSpark, Inc. 's 3. 39β — meaning CLSK is approximately 7% more volatile than HIVE relative to the S&P 500. On balance sheet safety, HIVE Digital Technologies Ltd. (HIVE) carries a lower debt/equity ratio of 12% versus 38% for CleanSpark, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — HIVE or CLSK?
By revenue growth (latest reported year), CleanSpark, Inc.
(CLSK) is pulling ahead at 102. 2% versus 0. 7% for HIVE Digital Technologies Ltd. (HIVE). On earnings-per-share growth, the picture is similar: CleanSpark, Inc. grew EPS 262. 3% year-over-year, compared to -108. 1% for HIVE Digital Technologies Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — HIVE or CLSK?
CleanSpark, Inc.
(CLSK) is the more profitable company, earning 47. 6% net margin versus -2. 6% for HIVE Digital Technologies Ltd. — meaning it keeps 47. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CLSK leads at 41. 6% versus 1. 4% for HIVE. At the gross margin level — before operating expenses — CLSK leads at 41. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — HIVE or CLSK?
In this comparison, CLSK (0.
2% yield) pays a dividend. HIVE does not pay a meaningful dividend and should not be held primarily for income.
07Is HIVE or CLSK better for a retirement portfolio?
For long-horizon retirement investors, HIVE Digital Technologies Ltd.
(HIVE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. CleanSpark, Inc. (CLSK) carries a higher beta of 3. 39 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HIVE: +27. 7%, CLSK: -84. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between HIVE and CLSK?
These companies operate in different sectors (HIVE (Financial Services) and CLSK (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: HIVE is a small-cap quality compounder stock; CLSK is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.